GT Biopharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GT Biopharma Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Oxis International, a biotechnology company focused on cannabinoid therapy development and commercialization, has named Dr Lisa A Haile a member of the scientific advisory board for its wholly owned subsidiary, Oxis Biotech. Dr Haile currently serves as co-chair, global life sciences sector at DLA Piper, where she is also a member of the firm's executive committee. She has specific technical expertise in molecular biology and immunology.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Large Molecule
- Other Names / Subsidiaries
- Georgetown Translational Pharmaceuticals, Inc.
- Oxis Biotech, Inc.
- Oxis International, Inc.